Xenon Pharmaceuticals vs Zenas BioPharma
XENE and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XENE and ZBIO compare
Xenon Pharmaceuticals is the larger company, worth 2.1 times as much as Zenas BioPharma ($3.9B against $1.8B).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XENE | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $1.8B |
| Share price | $40.48 | $28.01 |
| Change, 1 year | 2.0% | −21.8% |
| Change, 5 years | 39.6% | – |
| Beta (5Y) | 0.62 | 0.39 |
| Employees | 370 | 167 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.4× (better) | 8.6× |
| FCF yield | −9.1% (better) | −13.3% |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | −25.3% | – |
| Profitability | ||
| Return on equity | −50.3% (better) | −265% |
| Return on invested capital | −251% | – |
| Financial health | ||
| Debt / equity | 0.00 | 1.05 (better) |
| Current ratio | 21.19 (better) | 9.42 |
| Altman Z-score | 41.77 (better) | −1.46 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 94.0% |
| Held by insiders | 0.17% | 36.1% |
| Insider net buying, 12 months | −$20.3M | $11.4M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.6% | 27.3% |
Go deeper
- XENE stock overview
- XENE income statement
- XENE valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.